Connect with us

Politics

Millions of Diabetes Patients Could Face Drug Shortages by no deal Brexit

Published

on

According to the chair of the UK medicines regulator, the effects of no-deal Brexit on supplies of insulin could have disadvantages for millions of diabetes patients including the prime minister. Michael Rawlins has said that if UK crashes out of the EU, there would be serious problems for the country as every drop of insulin, a vital medication used by some 3.7 million people, is imported.

Michael of the Medicines and Healthcare Products Regulatory Agency (MHRA) has urged the officials to ensure drugs do not run out if no-deal Brexit happen. It comes as the new health secretary talked about the plans to stockpile drugs and medical and blood products in the situation of a no deal.

Michael said that there would be problems if the UK exit the EU and the Department of Health and Social Care need to know how to work. There would be problems as every drop of insulin is imported that couldn’t be transport ordinarily as it must be temperature-controlled.

 Disruption to the supply chain is one of the ways that patients could be seriously disadvantaged. It could be a reality if we don’t get our act together. We can’t suddenly start manufacturing insulin – it’s got to be sorted, no question.

Labour MP, Chris Leslie, expressed his concern over no-deal scenario that could be damaging for the country. He stated that insulin is a vital drug that millions of patients rely on it every day; the PM should stay in the EFA medicines regulatory network by the Commons votes while the government ignores it.

Theresa May wanted to reassure people that the government is in negotiation and is working for a good deal.

Twitter

FACEBOOK

Trending